author-photo

Meera Patturajan

Celgene

8

Papers

133

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

2018 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (7)
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

2016 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (94)
Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

2014 Blood
Show All
- Source
- Cite
- Save
Citations (19)
AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)